Transoma Medical Announces First Patient Enrollment in Clinical Study on Long-Term Cardiac Monitoring for Detection of Atrial Fibrillation after Cryptogenic Stroke

Published: Apr 14, 2009

ST. PAUL, Minn.--(BUSINESS WIRE)--Transoma Medical, Inc., manufacturer of Sleuth ATâ„¢, the only wireless, automated implantable cardiac monitoring system with programmable and frequent electrocardiogram (ECG) sampling, announced the first enrollment and implant in a long-term study to monitor patients who have suffered a cryptogenic stroke (of unknown origin) to determine if atrial fibrillation (AF) is present. The implant was performed on April 10 by Dr. Emile Daoud, electrophysiologist, at Ohio State University Medical Center in Columbus. The company received FDA 510(k) marketing clearance for Sleuth AT, its next-generation product, on Feb. 11, 2009.

Back to news